Targeting CARM1 in ovarian cancer with EZH2 and PARP inhibitors

Sergey Karakashev; Rugang Zhang

doi:10.1080/23723556.2020.1760675

Targeting CARM1 in ovarian cancer with EZH2 and PARP inhibitors

Sergey Karakashev, Rugang Zhang

Wistar Institute

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Coactivator-associated arginine methyltransferase 1 (CARM1)-expressing high-grade serous ovarian cancers are characterized by poor prognosis and limited therapeutic options. Here we discuss a novel therapeutic strategy to target CARM1-expressing ovarian cancer based on a combination of poly (ADP-ribose) polymerase (PARP) and enhancer of zeste homology 2 (EZH2) inhibitors.

Original language	English
Journal	Molecular and Cellular Oncology
Volume	7
Issue number	4
DOIs	https://doi.org/10.1080/23723556.2020.1760675
State	Published - 2020
Externally published	Yes

Keywords

coactivator-associated arginine methyltransferase 1 (CARM1) enhancer of zeste homology 2 (EZH2) inhibitors epithelial ovarian cancer homologous recombination (HR) immune checkpoint blockers mitotic arrest deficient 2 like 2 (MAD2L2) non-homologous end-joining (NHEJ) poly (ADP-ribose) polymerase (PARP) inhibitors

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/23723556.2020.1760675

Cite this

@article{9e27d151ae8c412189c739c6a44c1506,

title = "Targeting CARM1 in ovarian cancer with EZH2 and PARP inhibitors",

abstract = "Coactivator-associated arginine methyltransferase 1 (CARM1)-expressing high-grade serous ovarian cancers are characterized by poor prognosis and limited therapeutic options. Here we discuss a novel therapeutic strategy to target CARM1-expressing ovarian cancer based on a combination of poly (ADP-ribose) polymerase (PARP) and enhancer of zeste homology 2 (EZH2) inhibitors.",

keywords = "coactivator-associated arginine methyltransferase 1 (CARM1) enhancer of zeste homology 2 (EZH2) inhibitors epithelial ovarian cancer homologous recombination (HR) immune checkpoint blockers mitotic arrest deficient 2 like 2 (MAD2L2) non-homologous end-joining (NHEJ) poly (ADP-ribose) polymerase (PARP) inhibitors",

author = "Sergey Karakashev and Rugang Zhang",

note = "Karakashev, Sergey ORCID: https://orcid.org/0000-0002-9849-2714 Zhang, Rugang ORCID: https://orcid.org/0000-0002-7255-2360 P30 CA010815/CA/NCI NIH HHS/United States R01 CA163377/CA/NCI NIH HHS/United States Journal Article United States 2020/09/19 Mol Cell Oncol. 2020 May 23;7(4):1760675. doi: 10.1080/23723556.2020.1760675. eCollection 2020.",

year = "2020",

doi = "10.1080/23723556.2020.1760675",

language = "English",

volume = "7",

journal = "Molecular and Cellular Oncology",

issn = "2372-3556",

publisher = "Taylor and Francis Ltd.",

number = "4",

}

TY - JOUR

T1 - Targeting CARM1 in ovarian cancer with EZH2 and PARP inhibitors

AU - Karakashev, Sergey

AU - Zhang, Rugang

N1 - Karakashev, Sergey ORCID: https://orcid.org/0000-0002-9849-2714 Zhang, Rugang ORCID: https://orcid.org/0000-0002-7255-2360 P30 CA010815/CA/NCI NIH HHS/United States R01 CA163377/CA/NCI NIH HHS/United States Journal Article United States 2020/09/19 Mol Cell Oncol. 2020 May 23;7(4):1760675. doi: 10.1080/23723556.2020.1760675. eCollection 2020.

PY - 2020

Y1 - 2020

N2 - Coactivator-associated arginine methyltransferase 1 (CARM1)-expressing high-grade serous ovarian cancers are characterized by poor prognosis and limited therapeutic options. Here we discuss a novel therapeutic strategy to target CARM1-expressing ovarian cancer based on a combination of poly (ADP-ribose) polymerase (PARP) and enhancer of zeste homology 2 (EZH2) inhibitors.

AB - Coactivator-associated arginine methyltransferase 1 (CARM1)-expressing high-grade serous ovarian cancers are characterized by poor prognosis and limited therapeutic options. Here we discuss a novel therapeutic strategy to target CARM1-expressing ovarian cancer based on a combination of poly (ADP-ribose) polymerase (PARP) and enhancer of zeste homology 2 (EZH2) inhibitors.

KW - coactivator-associated arginine methyltransferase 1 (CARM1) enhancer of zeste homology 2 (EZH2) inhibitors epithelial ovarian cancer homologous recombination (HR) immune checkpoint blockers mitotic arrest deficient 2 like 2 (MAD2L2) non-homologous end-joi

U2 - 10.1080/23723556.2020.1760675

DO - 10.1080/23723556.2020.1760675

M3 - Article

SN - 2372-3556

VL - 7

JO - Molecular and Cellular Oncology

JF - Molecular and Cellular Oncology

IS - 4

ER -

Targeting CARM1 in ovarian cancer with EZH2 and PARP inhibitors

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this